EPA-话题@MedSci

#EPA#

1120篇内容 | 5257人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1427255, encodeId=620a142e25587, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, objectTitle=Lancet Gastroen Hepatol：低剂量丙咪嗪治疗难治性功能性消化不良, objectType=article, longId=151684, objectId=4e55151684ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e55151684ef, replyNumber=0, likeNumber=168, createdTime=2018-10-24, rootId=0, userName=gwc384, userId=4a9b4077760, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e55151684ef, moduleTitle=Lancet Gastroen Hepatol：低剂量丙咪嗪治疗难治性功能性消化不良, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e55151684ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1427254, encodeId=6170142e254ca, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, objectTitle=JCO：Epacadostat 联合 Pembrolizumab治疗晚期实体瘤, objectType=article, longId=150031, objectId=8f8f1500318b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f8f1500318b, replyNumber=0, likeNumber=143, createdTime=2018-10-01, rootId=0, userName=gwc384, userId=4a9b4077760, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f8f1500318b, moduleTitle=JCO：Epacadostat 联合 Pembrolizumab治疗晚期实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f8f1500318b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1427253, encodeId=336c142e2531c, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, objectTitle=Hepatol Res：在日本丙肝病毒基因2型感染患者中，SOF + RBV治疗是非常有效和安全的, objectType=article, longId=149811, objectId=1f6914981130, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f6914981130, replyNumber=0, likeNumber=120, createdTime=2018-09-29, rootId=0, userName=gwc384, userId=4a9b4077760, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f6914981130, moduleTitle=Hepatol Res：在日本丙肝病毒基因2型感染患者中，SOF + RBV治疗是非常有效和安全的, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f6914981130)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1427252, encodeId=f85d142e252f6, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, objectTitle=Hepatol Res：质子泵抑制剂治疗不会增加肝硬化患者血清内毒素水平, objectType=article, longId=149810, objectId=fef3149810d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fef3149810d8, replyNumber=0, likeNumber=105, createdTime=2018-09-29, rootId=0, userName=gwc384, userId=4a9b4077760, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fef3149810d8, moduleTitle=Hepatol Res：质子泵抑制剂治疗不会增加肝硬化患者血清内毒素水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fef3149810d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1427251, encodeId=ef8f142e25185, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, objectTitle=Hepatology：DAA治疗获得非晚期肝病患者获得SVR后，患者的死亡可得到改善, objectType=article, longId=149809, objectId=71c814980961, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71c814980961, replyNumber=0, likeNumber=109, createdTime=2018-09-29, rootId=0, userName=gwc384, userId=4a9b4077760, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71c814980961, moduleTitle=Hepatology：DAA治疗获得非晚期肝病患者获得SVR后，患者的死亡可得到改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71c814980961)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1427250, encodeId=69ba142e25057, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, objectTitle=Hepatology：在中-晚期肝癌患者中，肝切除和化疗栓塞两种治疗方法的比较, objectType=article, longId=149807, objectId=315514980e34, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=315514980e34, replyNumber=0, likeNumber=81, createdTime=2018-09-29, rootId=0, userName=gwc384, userId=4a9b4077760, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=315514980e34, moduleTitle=Hepatology：在中-晚期肝癌患者中，肝切除和化疗栓塞两种治疗方法的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=315514980e34)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1427249, encodeId=ede8142e2496f, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, objectTitle=Hepatology：鞘氨醇激酶1通过促进CCR2的表达来促进肝纤维化, objectType=article, longId=149804, objectId=123b14980401, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=123b14980401, replyNumber=0, likeNumber=81, createdTime=2018-09-29, rootId=0, userName=gwc384, userId=4a9b4077760, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=123b14980401, moduleTitle=Hepatology：鞘氨醇激酶1通过促进CCR2的表达来促进肝纤维化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=123b14980401)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1427248, encodeId=4cad142e2481b, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, objectTitle=Hepatology：年龄、性别，而非ATP7B 基因型影响Wilson疾病的临床表型, objectType=article, longId=149614, objectId=98e714961408, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98e714961408, replyNumber=0, likeNumber=101, createdTime=2018-09-27, rootId=0, userName=gwc384, userId=4a9b4077760, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98e714961408, moduleTitle=Hepatology：年龄、性别，而非ATP7B 基因型影响Wilson疾病的临床表型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=98e714961408)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1427247, encodeId=a87b142e24788, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, objectTitle=Hepatology：美国非酒精性脂肪性肝炎的疾病负担, objectType=article, longId=149613, objectId=4c6a149613c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c6a149613c4, replyNumber=0, likeNumber=119, createdTime=2018-09-27, rootId=0, userName=gwc384, userId=4a9b4077760, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c6a149613c4, moduleTitle=Hepatology：美国非酒精性脂肪性肝炎的疾病负担, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c6a149613c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1427246, encodeId=dca8142e2469f, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, objectTitle=Hepatology：CCR2/CCR5抑制剂—CVC可减轻酒精诱导的脂肪肝性肝炎和肝损伤, objectType=article, longId=149612, objectId=7fe814961202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fe814961202, replyNumber=0, likeNumber=92, createdTime=2018-09-27, rootId=0, userName=gwc384, userId=4a9b4077760, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fe814961202, moduleTitle=Hepatology：CCR2/CCR5抑制剂—CVC可减轻酒精诱导的脂肪肝性肝炎和肝损伤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7fe814961202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1427245, encodeId=9acc142e245c0, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, objectTitle=Hepatology：在美国，慢性乙型肝炎患者的并发症和发病年龄, objectType=article, longId=149611, objectId=8d4d149611be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d4d149611be, replyNumber=0, likeNumber=110, createdTime=2018-09-27, rootId=0, userName=gwc384, userId=4a9b4077760, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d4d149611be, moduleTitle=Hepatology：在美国，慢性乙型肝炎患者的并发症和发病年龄, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d4d149611be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1427244, encodeId=5d5e142e244ec, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, objectTitle=Lancet Gastroen Hepatol：贝伐单抗生物类似物BEVZ92用于转移性结肠癌一线治疗, objectType=article, longId=149567, objectId=76c414956ed4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76c414956ed4, replyNumber=0, likeNumber=96, createdTime=2018-09-27, rootId=0, userName=gwc384, userId=4a9b4077760, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76c414956ed4, moduleTitle=Lancet Gastroen Hepatol：贝伐单抗生物类似物BEVZ92用于转移性结肠癌一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76c414956ed4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1427243, encodeId=690d142e243c2, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, objectTitle=Hepatology：血管生成素2是CHC患者接受DAA治疗后，HCC复发或新发的重要预测因素, objectType=article, longId=149526, objectId=cefb1495267d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cefb1495267d, replyNumber=0, likeNumber=85, createdTime=2018-09-26, rootId=0, userName=gwc384, userId=4a9b4077760, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cefb1495267d, moduleTitle=Hepatology：血管生成素2是CHC患者接受DAA治疗后，HCC复发或新发的重要预测因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cefb1495267d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1427242, encodeId=3dbd142e2426f, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, objectTitle=Hepatology：美国参加私人保险人员的酒精性肝硬化的流行率、卫生保健状况和治疗成本, objectType=article, longId=149524, objectId=30f4149524e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30f4149524e6, replyNumber=0, likeNumber=78, createdTime=2018-09-26, rootId=0, userName=gwc384, userId=4a9b4077760, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30f4149524e6, moduleTitle=Hepatology：美国参加私人保险人员的酒精性肝硬化的流行率、卫生保健状况和治疗成本, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30f4149524e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1427241, encodeId=3568142e241b4, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, objectTitle=J Hepatol：DAA治疗对肝移植的影响：对适应症和结果演变的影响, objectType=article, longId=149472, objectId=1bf71494e28c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bf71494e28c, replyNumber=0, likeNumber=95, createdTime=2018-09-25, rootId=0, userName=gwc384, userId=4a9b4077760, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bf71494e28c, moduleTitle=J Hepatol：DAA治疗对肝移植的影响：对适应症和结果演变的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1bf71494e28c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1427240, encodeId=42f4142e24056, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, objectTitle=J Hepatol：2016-2030年间，中国、法国、德国、意大利、日本、西班牙、英国和美国等国家的NAFLD负担, objectType=article, longId=149471, objectId=91c71494e119, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91c71494e119, replyNumber=0, likeNumber=69, createdTime=2018-09-25, rootId=0, userName=gwc384, userId=4a9b4077760, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91c71494e119, moduleTitle=J Hepatol：2016-2030年间，中国、法国、德国、意大利、日本、西班牙、英国和美国等国家的NAFLD负担, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91c71494e119)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1427239, encodeId=323f142e239e4, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, objectTitle=J Hepatol：在肝纤维化过程中，P2X4可调节肌成纤维细胞激活, objectType=article, longId=149470, objectId=5d5c1494e0c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d5c1494e0c4, replyNumber=0, likeNumber=92, createdTime=2018-09-25, rootId=0, userName=gwc384, userId=4a9b4077760, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d5c1494e0c4, moduleTitle=J Hepatol：在肝纤维化过程中，P2X4可调节肌成纤维细胞激活, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d5c1494e0c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1427238, encodeId=78a0142e23862, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, objectTitle=J Hepatol：Sofosbuvir/velpatasvir治疗HCV基因1-4型肝移植患者，疗效显著且安全, objectType=article, longId=149345, objectId=898214934537, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=898214934537, replyNumber=0, likeNumber=128, createdTime=2018-09-23, rootId=0, userName=gwc384, userId=4a9b4077760, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=898214934537, moduleTitle=J Hepatol：Sofosbuvir/velpatasvir治疗HCV基因1-4型肝移植患者，疗效显著且安全, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=898214934537)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1427236, encodeId=0366142e23684, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, objectTitle=J Hepatol：在抗病毒治疗期间，ALT水平正常与慢性乙型肝炎患者肝脏事件的风险降低有关, objectType=article, longId=149273, objectId=5fe91492e39e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5fe91492e39e, replyNumber=0, likeNumber=85, createdTime=2018-09-22, rootId=0, userName=gwc384, userId=4a9b4077760, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5fe91492e39e, moduleTitle=J Hepatol：在抗病毒治疗期间，ALT水平正常与慢性乙型肝炎患者肝脏事件的风险降低有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5fe91492e39e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1427237, encodeId=2855142e23796, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, objectTitle=J Hepatol：社区保健中心CHC患者肝脏硬度增加的流行率和探究晚期肝脏疾病、肝脏相关事件的预测因素, objectType=article, longId=149274, objectId=01ca1492e432, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01ca1492e432, replyNumber=0, likeNumber=101, createdTime=2018-09-22, rootId=0, userName=gwc384, userId=4a9b4077760, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01ca1492e432, moduleTitle=J Hepatol：社区保健中心CHC患者肝脏硬度增加的流行率和探究晚期肝脏疾病、肝脏相关事件的预测因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=01ca1492e432)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

EPA

2020-05-29

gwc384 (审核中...)

前往app查看评论内容

#EPA#

Lancet Gastroen Hepatol：低剂量丙咪嗪治疗难治性功能性消化不良

2018-10-24

gwc384 (审核中...)

前往app查看评论内容

#EPA#

JCO：Epacadostat 联合 Pembrolizumab治疗晚期实体瘤

2018-10-01

gwc384 (审核中...)

前往app查看评论内容

#EPA#

Hepatol Res：在日本丙肝病毒基因2型感染患者中，SOF + RBV治疗是非常有效和安全的

2018-09-29

gwc384 (审核中...)

前往app查看评论内容

#EPA#

Hepatol Res：质子泵抑制剂治疗不会增加肝硬化患者血清内毒素水平

2018-09-29

gwc384 (审核中...)

前往app查看评论内容

#EPA#

Hepatology：DAA治疗获得非晚期肝病患者获得SVR后，患者的死亡可得到改善

2018-09-29

gwc384 (审核中...)

前往app查看评论内容

#EPA#

Hepatology：在中-晚期肝癌患者中，肝切除和化疗栓塞两种治疗方法的比较

2018-09-29

gwc384 (审核中...)

前往app查看评论内容

#EPA#

Hepatology：鞘氨醇激酶1通过促进CCR2的表达来促进肝纤维化

2018-09-29

gwc384 (审核中...)

前往app查看评论内容

#EPA#

Hepatology：年龄、性别，而非ATP7B 基因型影响Wilson疾病的临床表型

2018-09-27

gwc384 (审核中...)

前往app查看评论内容

#EPA#

Hepatology：美国非酒精性脂肪性肝炎的疾病负担

2018-09-27

gwc384 (审核中...)

前往app查看评论内容

#EPA#

Hepatology：CCR2/CCR5抑制剂—CVC可减轻酒精诱导的脂肪肝性肝炎和肝损伤

2018-09-27

gwc384 (审核中...)

前往app查看评论内容

#EPA#

Hepatology：在美国，慢性乙型肝炎患者的并发症和发病年龄

2018-09-27

gwc384 (审核中...)

前往app查看评论内容

#EPA#

Lancet Gastroen Hepatol：贝伐单抗生物类似物BEVZ92用于转移性结肠癌一线治疗

2018-09-27

gwc384 (审核中...)

前往app查看评论内容

#EPA#

Hepatology：血管生成素2是CHC患者接受DAA治疗后，HCC复发或新发的重要预测因素

2018-09-26

gwc384 (审核中...)

前往app查看评论内容

#EPA#

Hepatology：美国参加私人保险人员的酒精性肝硬化的流行率、卫生保健状况和治疗成本

2018-09-26

gwc384 (审核中...)

前往app查看评论内容

#EPA#

J Hepatol：DAA治疗对肝移植的影响：对适应症和结果演变的影响

2018-09-25

gwc384 (审核中...)

前往app查看评论内容

#EPA#

J Hepatol：2016-2030年间，中国、法国、德国、意大利、日本、西班牙、英国和美国等国家的NAFLD负担

2018-09-25

gwc384 (审核中...)

前往app查看评论内容

#EPA#

J Hepatol：在肝纤维化过程中，P2X4可调节肌成纤维细胞激活

2018-09-25

gwc384 (审核中...)

前往app查看评论内容

#EPA#

J Hepatol：Sofosbuvir/velpatasvir治疗HCV基因1-4型肝移植患者，疗效显著且安全

2018-09-23

gwc384 (审核中...)

前往app查看评论内容

#EPA#

J Hepatol：在抗病毒治疗期间，ALT水平正常与慢性乙型肝炎患者肝脏事件的风险降低有关

2018-09-22

gwc384 (审核中...)

前往app查看评论内容

#EPA#

J Hepatol：社区保健中心CHC患者肝脏硬度增加的流行率和探究晚期肝脏疾病、肝脏相关事件的预测因素

2018-09-22

科室
- - 订阅+
  - 更多科室
工具
服务